Human medicines European public assessment report (EPAR): Upstaza, eladocagene exuparvovec, Date of authorisation: 18/07/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Upstaza, eladocagene exuparvovec, Date of authorisation: 18/07/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Wezenla, ustekinumab, Date of authorisation: 20/06/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Wezenla, ustekinumab, Date of authorisation: 20/06/2024, Revision: 4, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Hepizovac, epizootic haemorrhagic disease vaccine (inactivated), Status: Authorised

Veterinary medicines European public assessment report (EPAR): Hepizovac, epizootic haemorrhagic disease vaccine (inactivated), Status: Authorised

Veterinary medicines European public assessment report (EPAR): Nobilis Multriva IBm+ND+EDS, infectious bronchitis,Newcastle disease,egg drop syndrome virus vaccine (inactivated), Status: Authorised

Veterinary medicines European public assessment report (EPAR): Nobilis Multriva IBm+ND+EDS, infectious bronchitis,Newcastle disease,egg drop syndrome virus vaccine (inactivated), Status: Authorised

Human medicines European public assessment report (EPAR): Prasugrel Viatris (previously Prasugrel Mylan), prasugrel, Date of authorisation: 15/05/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Prasugrel Viatris (previously Prasugrel Mylan), prasugrel, Date of authorisation: 15/05/2018, Revision: 12, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.